-$0.22 EPS Expected for BioCryst Pharmaceuticals, Inc. (BCRX) This Quarter

Wall Street brokerages predict that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will announce earnings per share of ($0.22) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for BioCryst Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.25). BioCryst Pharmaceuticals reported earnings per share of ($0.20) during the same quarter last year, which suggests a negative year over year growth rate of 10%. The firm is scheduled to issue its next earnings report on Tuesday, February 26th.

On average, analysts expect that BioCryst Pharmaceuticals will report full year earnings of ($0.96) per share for the current year, with EPS estimates ranging from ($1.00) to ($0.89). For the next financial year, analysts forecast that the business will report earnings of ($1.00) per share, with EPS estimates ranging from ($1.09) to ($0.93). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). BioCryst Pharmaceuticals had a negative return on equity of 145.89% and a negative net margin of 428.00%. The business had revenue of $1.45 million for the quarter, compared to the consensus estimate of $2.53 million.

BCRX has been the subject of a number of research reports. Bank of America raised BioCryst Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, July 17th. BidaskClub cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 21st. Royal Bank of Canada reissued a “buy” rating and set a $9.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 7th. ValuEngine raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, August 8th. Finally, JPMorgan Chase & Co. initiated coverage on BioCryst Pharmaceuticals in a research note on Wednesday, August 8th. They set an “overweight” rating and a $9.00 target price for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $9.89.

NASDAQ BCRX traded down $0.39 during trading hours on Friday, reaching $7.70. 512,158 shares of the company’s stock were exchanged, compared to its average volume of 841,949. BioCryst Pharmaceuticals has a one year low of $4.25 and a one year high of $8.31. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.25 and a current ratio of 1.25. The stock has a market cap of $851.55 million, a price-to-earnings ratio of -9.87 and a beta of 1.75.

In other news, insider Thomas R. Staab II sold 9,850 shares of the firm’s stock in a transaction that occurred on Wednesday, October 3rd. The shares were sold at an average price of $7.24, for a total transaction of $71,314.00. Following the completion of the transaction, the insider now directly owns 140,633 shares of the company’s stock, valued at approximately $1,018,182.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Lynne Powell sold 5,280 shares of the firm’s stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $8.15, for a total transaction of $43,032.00. Following the transaction, the vice president now directly owns 8,905 shares of the company’s stock, valued at $72,575.75. The disclosure for this sale can be found here. Insiders have sold a total of 45,182 shares of company stock valued at $352,176 over the last ninety days. Company insiders own 4.50% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of BCRX. Janus Henderson Group PLC grew its stake in shares of BioCryst Pharmaceuticals by 45.0% during the 2nd quarter. Janus Henderson Group PLC now owns 11,096,183 shares of the biotechnology company’s stock worth $63,581,000 after acquiring an additional 3,441,498 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 13.1% in the 3rd quarter. BlackRock Inc. now owns 8,769,856 shares of the biotechnology company’s stock valued at $66,914,000 after buying an additional 1,013,905 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 10.9% in the 3rd quarter. Jennison Associates LLC now owns 3,850,003 shares of the biotechnology company’s stock valued at $29,376,000 after buying an additional 378,565 shares during the last quarter. VHCP Management II LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 11.0% in the 2nd quarter. VHCP Management II LLC now owns 2,464,241 shares of the biotechnology company’s stock valued at $14,120,000 after buying an additional 243,270 shares during the last quarter. Finally, UBS Group AG boosted its holdings in shares of BioCryst Pharmaceuticals by 190.7% in the 1st quarter. UBS Group AG now owns 291,379 shares of the biotechnology company’s stock valued at $1,390,000 after buying an additional 191,157 shares during the last quarter. 79.82% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Featured Article: What is a put option?

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply